Extracted from this filing and checked against the source text.
Listing & Compliance Notices
SEC 8-K Item 3.01
confidence 0.9
Alzamend Neuro, Inc. received a nasdaq noncompliance notice notice regarding market value (rules 5550(b)(2)).
- Exchange
- nasdaq
- Notice
- noncompliance notice
- Deficiency
- market value
- Rules
- 5550(b)(2)
Exact text from the filing
September 26, 2023, Alzamend Neuro, Inc. (the “Company” ) received a notice from the staff of The Nasdaq Stock Market LLC (“ Nasdaq ”) indicating that, for the previous 30 consecutive business days, the minimum Market Value of Listed Securities (“ MVLS ”) for the Company’s common stock, par value $0.0001 per share (the “Common Stock” ), was below the $35 million minimum MVLS requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(2) (the “ MVLS Rule ”). In accordance with Nasdaq Listing Rule 5810(c)(3)(C), the Company will have 180 calendar days, or unt
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Alzamend Neuro, Inc. shareholders approved Approval of the amendment to the Company's Certificate of Incorporation to effect a reverse stock split of the Common Stock by a ratio of not less than one-for-two and not more than one-for-twenty at any time prior to September 28, 2024 at the 2023-09-29 meeting.
- Proposal
- reverse split
- Outcome
- passed
- Meeting
- 2023-09-29
Exact text from the filing
Proposal One : Approval of the amendment to the Company’s Certificate of Incorporation to effect a reverse stock split of the Common Stock by a ratio of not less than one-for-two and not more than one-for-twenty at any time prior to September 28, 2024, with the exact ratio to be set at a whole number within this range as determined by the Company’s Board of Directors in its sole discretion.
View on SEC.gov